Drug
LT-02
LT-02 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 33.3%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(50%)
Phase Distribution
Ph phase_3
3
75%
Ph phase_2
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(1)
Terminated(2)
Other(1)
Detailed Status
Terminated2
Completed1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
33.3%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (25.0%)
Phase 33 (75.0%)
Trials by Status
terminated250%
completed125%
unknown125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)
NCT02280629
terminatedphase_3
A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
NCT02849951
terminatedphase_3
Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis
NCT02142725
unknownphase_2
A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis
NCT01011322
Clinical Trials (4)
Showing 4 of 4 trials
NCT02280629Phase 3
Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)
NCT02849951Phase 3
A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
NCT02142725Phase 3
Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis
NCT01011322Phase 2
A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4